Safety and Efficacy of nab-Paclitaxel in the Treatment of Patients with Breast Cancer.

Breast Cancer (Auckl) · 2011 · PMC3091407 · PMID 21603258

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

On the basis of independent radiologist review, both 150 mg/m 2 (49%) and 100 mg/m 2 (45%) weekly nab- paclitaxel demonstrated a higher ORR than docetaxel (35%), but this did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.